Douglas Hedley

1.6k total citations
14 papers, 1.2k citations indexed

About

Douglas Hedley is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Douglas Hedley has authored 14 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Oncology and 5 papers in Genetics. Recurrent topics in Douglas Hedley's work include Melanoma and MAPK Pathways (6 papers), Virus-based gene therapy research (5 papers) and Cancer Research and Treatments (5 papers). Douglas Hedley is often cited by papers focused on Melanoma and MAPK Pathways (6 papers), Virus-based gene therapy research (5 papers) and Cancer Research and Treatments (5 papers). Douglas Hedley collaborates with scholars based in United Kingdom, United States and France. Douglas Hedley's co-authors include Lesley Ogilvie, Caroline J. Springer, Richard Marais, Jan Martin, Dan Niculescu‐Duvaz, Maria Karasarides, Robert Hayward, Frank Friedlos, Ian Scanlon and Claudia Wellbrock and has published in prestigious journals such as Nature reviews. Cancer, Cancer Research and Oncogene.

In The Last Decade

Douglas Hedley

14 papers receiving 1.2k citations

Peers

Countries citing papers authored by Douglas Hedley

Since Specialization

Citations

This map shows the geographic impact of Douglas Hedley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Hedley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Hedley more than expected).

Fields of papers citing papers by Douglas Hedley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Hedley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Hedley. The network helps show where Douglas Hedley may publish in the future.

Co-authorship network of co-authors of Douglas Hedley

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Hedley. A scholar is included among the top collaborators of Douglas Hedley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Hedley. Douglas Hedley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	A Novel, Selective, and Efficacious Nanomolar Pyridopyrazinone Inhibitor of V600EBRAF 2010 ·Cancer Research ·Steven R. Whittaker, Delphine Ménard, Richard Kirk, Lesley Ogilvie, Douglas Hedley, Alfonso Zambon, Filipa M. Lopes, Natasha Preece, (unknown), Sareena Rana, Maryou Lambros, Jorge S. Reis‐Filho, Richard Marais, Caroline J. Springer	15
2	Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds 2010 ·Bioorganic & Medicinal Chemistry ·Dan Niculescu‐Duvaz, Ion Niculescu‐Duvaz, Bart M. J. M. Suijkerbuijk, Delphine Ménard, Alfonso Zambon, Arnaud Nourry, Lawrence Davies, (unknown), Frank Friedlos, Lesley Ogilvie, Douglas Hedley, Andrew K. Takle, David M. Wilson, Jean‐François Pons, (unknown), Richard Kirk, Neus Cantariño, Steven R. Whittaker, Richard Marais, Caroline J. Springer	28
3	Novel Hinge Binder Improves Activity and Pharmacokinetic Properties of BRAF Inhibitors 2010 ·Journal of Medicinal Chemistry ·Alfonso Zambon, Delphine Ménard, Bart M. J. M. Suijkerbuijk, Ion Niculescu‐Duvaz, Steven R. Whittaker, Dan Niculescu‐Duvaz, Arnaud Nourry, Lawrence Davies, (unknown), Filipa M. Lopes, Natasha Preece, Douglas Hedley, Lesley Ogilvie, Richard Kirk, Richard Marais, Caroline J. Springer	31
4	Inducible expression of^V600EBraf using tyrosinase-driven Cre recombinase results in embryonic lethality 2009 ·Pigment Cell & Melanoma Research ·Nathalie Dhomen, Silvy da Rocha Dias, Robert Hayward, Lesley Ogilvie, Douglas Hedley, Véronique Delmas, Afshan McCarthy, Deborah J. Henderson, Caroline J. Springer, Catrin Pritchard, Lionel Larue, Richard Marais	18
5	Attenuated Salmonella Targets Prodrug Activating Enzyme Carboxypeptidase G2 to Mouse Melanoma and Human Breast and Colon Carcinomas for Effective Suicide Gene Therapy 2008 ·Clinical Cancer Research ·Frank Friedlos, Panos Lehouritis, Lesley Ogilvie, Douglas Hedley, Lawrence Davies, David Bermudes, Ivan King, Jan Martin, Richard Marais, Caroline J. Springer	76
6	Carboxypeptidase G2-based gene-directed enzyme–prodrug therapy: a new weapon in the GDEPT armoury 2007 ·Nature reviews. Cancer ·Douglas Hedley, Lesley Ogilvie, Caroline J. Springer	58
7	Suicide Gene Therapy of Human Colon Carcinoma Xenografts Using an Armed Oncolytic Adenovirus Expressing Carboxypeptidase G2 2007 ·Cancer Research ·Silke Schepelmann, Lesley Ogilvie, Douglas Hedley, Frank Friedlos, Janet L. Martin, Ian Scanlon, Ping Chen, Richard Marais, Caroline J. Springer	50
8	In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP Signaling 2006 ·Cancer Research ·Nicolas Dumaz, Robert Hayward, Jan Martin, Lesley Ogilvie, Douglas Hedley, John A. Curtin, Boris C. Bastian, Caroline J. Springer, Richard Marais	241
9	Systemic Gene-Directed Enzyme Prodrug Therapy of Hepatocellular Carcinoma Using a Targeted Adenovirus Armed with Carboxypeptidase G2 2005 ·Cancer Research ·Silke Schepelmann, Paul L. Hallenbeck, Lesley Ogilvie, Douglas Hedley, Frank Friedlos, Janet L. Martin, Ian Scanlon, Carl Hay, Lynda K. Hawkins, Richard Marais, Caroline J. Springer	27
10	Novel Fluorinated Prodrugs for Activation by Carboxypeptidase G2 Showing Good in Vivo Antitumor Activity in Gene-Directed Enzyme Prodrug Therapy 2005 ·Journal of Medicinal Chemistry ·Lawrence Davies, Frank Friedlos, Douglas Hedley, Jan Martin, Lesley Ogilvie, Ian Scanlon, Caroline J. Springer	23
11	B-RAF is a therapeutic target in melanoma 2004 ·Oncogene ·Maria Karasarides, Antonio Chiloeches, Robert Hayward, Dan Niculescu‐Duvaz, Ian Scanlon, Frank Friedlos, Lesley Ogilvie, Douglas Hedley, Jan Martin, Christopher J. Marshall, Caroline J. Springer, Richard Marais	360
12	V599EB-RAF is an Oncogene in Melanocytes 2004 ·Cancer Research ·Claudia Wellbrock, Lesley Ogilvie, Douglas Hedley, Maria Karasarides, Jan Martin, Dan Niculescu‐Duvaz, Caroline J. Springer, Richard Marais	271
13	Proinsecticides effective against insecticide‐resistant peach‐potato aphid ( Myzus persicae (Sulzer)) 1998 ·Pesticide Science ·Douglas Hedley, Bhupinder P. S. Khambay, Antony M. Hooper, Richard Thomas, A. L. Devonshire	13
14	Thyroliberin (TRH), 6-methyl-5-oxothiomorpholinyl-3-carbonyl histidylproline amide and histidylproline diketopiperazine do not affect the release of [3H]-acetyl choline and [3H]-choline from rat brain tissue cubes 1985 ·Biochemical Pharmacology ·Douglas Hedley, Peter F. T. Vaughan	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact